Special Drug Use Investigation of EYLEA for Diabetic Macular Edema
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors Bayer
- 26 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 23 Nov 2016 Planned number of patients changed from 627 to 647.
- 23 Sep 2016 Planned number of patients changed from 600 to 627.